Ascendis Pharma A/S
ASND
35 hedge funds and large institutions have $585M invested in Ascendis Pharma A/S in 2017 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 10 increasing their positions, 12 reducing their positions, and 3 closing their positions.
167% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 3
63% more capital inflows, than outflows
Capital inflows: $31.5M | Capital outflows: $19.3M
13% more funds holding
Funds holding: 31 → 35 (+4)
0.59% more ownership
Funds ownership: 36.15% → 36.74% (+0.59%)
0% more funds holding in top 10
Funds holding in top 10: 7 → 7 (0)
17% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
+$8.29M |
| 2 |
OppenheimerFunds
New York
|
+$7.52M |
| 3 |
Avoro Capital Advisors
New York
|
+$3.94M |
| 4 |
VHCP Management II
New York
|
+$2.28M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$2.18M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deerfield Management
New York
|
-$3.05M |
| 2 |
Millennium Management
New York
|
-$2.23M |
| 3 |
Nexthera Capital
New York
|
-$2.02M |
| 4 |
Foresite Capital Management III
Larkspur,
California
|
-$2.02M |
| 5 |
Sphera Funds Management
Tel Aviv,
Israel
|
-$1.8M |
ASND Hedge Fund Activity: Q1 2017 in Review
35 of the 4,035 institutional investors tracked by Wall St. Rank reported a position in Ascendis Pharma A/S (ASND) for Q1 2017, worth a combined $585M — up 41% from $416M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new ASND positions and 3 closed out — a net gain of 5 holders — while 10 added to existing stakes and 12 trimmed.
The largest buyer was Baker Bros. Advisors, adding an estimated $8.29M. The largest seller was Deerfield Management, cutting an estimated $3.05M.
- 35 institutional investors held Ascendis Pharma A/S (ASND) as of Q1 2017, up from 31 in Q4 2016.
- Funds reported $585M of Ascendis Pharma A/S stock for Q1 2017, up 41% quarter-over-quarter.
- 8 funds opened new Ascendis Pharma A/S positions in Q1 2017 and 3 closed out, a net change of +5 holders.
- The largest Ascendis Pharma A/S buyer in Q1 2017 was Baker Bros. Advisors, an estimated $8.29M added.
- The largest Ascendis Pharma A/S seller in Q1 2017 was Deerfield Management, an estimated $3.05M sold.
Based on aggregated 13F filings for Q1 2017.